ALDH7A1 and neoplasm: Our discovery and in vivo efficacy demonstration of an agent that can inhibit tumor growth in a PDE3A-dependent manner without affecting the enzyme activity of PDE3A supports the clinically attractive idea that using a PDE3-targeting strategy to develop anticancer therapies may preclude some of the side effects known to accompany chemical inhibition of PDE3A’s PDE activity.